The ability to correctly diagnose and institute effective periodontal therapy is essential to control periodontal diseases. Rapid advances in diagnostic research are moving towards methods whereby periodontal disease risk can be identified and quantified by measuring biomarkers. This study investigated the effect of Non-Surgical Periodontal Treatment (NSPT) on clinical indices and salivary levels of visfatin in subjects with increasing severity of the periodontal disease. This interventional clinical trial was performed on 60 systemically healthy male and female subjects (20 to 50 years) who were categorised into Group-1, Twenty subjects with healthy periodontium, Group-2, Twenty subjects with generalized moderate gingivitis, and Group-3 (20 subjects with moderate to severe periodontitis (Stage III according to the new classification of periodontal diseases). The visfatin levels were measured in unstimulated saliva by using standard EnzymeLinked Immunosorbent Assay (ELISA) technique at baseline and six weeks after NSPT. The salivary visfatin levels were highest in Group-3 (38.22±3.38 ng/ml) followed by Group - 2 (26.66±2.24 ng/ml) and Group-1 (25.60±2.19 ng/ml) at baseline. After NSPT statistically significant reduction in salivary visfatin levels (p<0.001) in Groups -2 and 3 were seen. Visfatin levels at baseline were almost equivocal in normal weight and overweight subjects, irrespective of body mass index and showed a statistically significant reduction in salivary visfatin levels in both groups six weeks after NSPT (p<0.001). The present study suggests that salivary visfatin is a strong contributor in the pathology of periodontal disease and can be used as its diagnostic/therapeutic biomarker.